{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T15:18:00Z","timestamp":1775661480424,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T00:00:00Z","timestamp":1364428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To study the influence of several factors (rheumatoid factor [RF], anti\u2013cyclic citrullinated peptide [anti\u2010CCP], serum Ig level, and Epstein\u2010Barr virus [EBV] load) on clinical response to rituximab (RTX) after 6 months in rheumatoid arthritis (RA) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sixty\u2010four patients receiving RTX (two 1\u2010gm doses 2 weeks apart) for active RA were prospectively included. RF, anti\u2010CCP, gamma globulin level, and EBV load were assessed prior to the first RTX cycle. Clinical responses were analyzed 6 months after RTX initiation using the European League Against Rheumatism criteria. Univariate and multivariate analyses were performed to identify factors associated with RTX response at 6 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean disease duration was 16.4 years and 46 patients (71.9%) had already received at least 1 anti\u2013tumor necrosis factor agent prior to RTX. At 6 months, 46 patients (71.9%) had a good to moderate response to RTX. Anti\u2010CCP positivity was associated with a good to moderate response (odds ratio [OR] 4, 95% confidence interval [95% CI] 1.04\u201315.5; <jats:italic>P<\/jats:italic> = 0.04). RF positivity (<jats:italic>P<\/jats:italic> = 0.26) and positive initial EBV load (<jats:italic>P<\/jats:italic> = 0.16) were not associated with a good to moderate response. Hyperimmunoglobulin was correlated with a poorer response to RTX than normal Ig levels (OR 0.04, 95% CI 0.005\u20130.28; <jats:italic>P<\/jats:italic> = 0.002).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Anti\u2010CCP positivity was a predictor of good to moderate response to RTX in RA patients. On the other hand, high Ig levels were associated with a poorer outcome in contrast to previous findings. Further support from larger studies is necessary so as to optimize the management of the RA patients with high Ig levels.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.21865","type":"journal-article","created":{"date-parts":[[2012,10,8]],"date-time":"2012-10-08T13:23:57Z","timestamp":1349702637000},"page":"648-652","source":"Crossref","is-referenced-by-count":35,"title":["Predictive Factors of Rituximab Response in Rheumatoid Arthritis: Results From a French University Hospital"],"prefix":"10.1002","volume":"65","author":[{"given":"M.","family":"Couderc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Glace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Soubrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,28]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.148759"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep314"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110610"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10933"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq159"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.30233"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_6_11_2","first-page":"705","article-title":"ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials","volume":"26","author":"Van Gestel AM","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.30599"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23473"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.074229"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080960"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2773"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.21865","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.21865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:20:44Z","timestamp":1759425644000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.21865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,28]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1002\/acr.21865"],"URL":"https:\/\/doi.org\/10.1002\/acr.21865","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,28]]}}}